170902-52-0

Basic information

• Product Name: 3-[3-(4-Amidinophenyl)-4,5-dihydroisoxazol-5(R)-ylacetamido]-2(S)-(butoxycarbonylamino)propionic acid
• Synonyms: XP-280(as besilate); XV-459; 3-[2-[3-(4-Amidinophenyl)-4,5-dihydroisoxazol-5(R)-yl]acetamido]-N-(butoxycarbonyl)-L-alanine; N-(butoxycarbonyl)-3-({[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl}amino)-L-alanine
• CAS NO: 170902-52-0
• Molecular Formula: C₂₀H₂₇N₅O₆
• Molecular Weight: 433.4583
• Mol File: 170902-52-0.mol

Chemical Properties

• Density: 1.41g/cm³
• Refractive Index: 1.627
• CAS DataBase Reference: 3-[3-(4-Amidinophenyl)-4,5-dihydroisoxazol-5(R)-ylacetamido]-2(S)-(butoxycarbonylamino)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[3-(4-Amidinophenyl)-4,5-dihydroisoxazol-5(R)-ylacetamido]-2(S)-(butoxycarbonylamino)propionic acid(170902-52-0)
• EPA Substance Registry System: 3-[3-(4-Amidinophenyl)-4,5-dihydroisoxazol-5(R)-ylacetamido]-2(S)-(butoxycarbonylamino)propionic acid(170902-52-0)

Safety Data

• Hazardous Substances Data: 170902-52-0(Hazardous Substances Data)

Upstream product

• 190446-72-1 (S)-2-Butoxycarbonylamino-3-{2-[3-(4-carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-propionic acid methyl ester 
• 190446-43-6 (S)-3-{2-[3-(4-{Amino-[(E)-tert-butoxycarbonylimino]-methyl}-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-benzyloxycarbonylamino-propionic acid methyl ester 
• 190446-44-7 methyl 3-[({3-[4-({[(1,1-dimethylethoxy)carbonyl]amino}iminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl}acetyl)amino]-N-[(phenylmethoxy)carbonyl]-L-alanine 
• 170726-52-0 methyl (R,S)-3-(4-{[N-(dimethylethoxycarbonyl)imino]aminomethyl}phenyl)-4,5-dihydro-5-isoxazoleacetate 
• 170726-53-1 (R,S)-3-(4-{[N-(dimethylethoxycarbonyl)imino]aminomethyl}phenyl)-4,5-dihydro-5-isoxazoleacetic acid 
• 170229-13-7 [3-(4-cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid 
• 52707-54-7 4-cyanobenzaldehyde oxime 

Relevant articles and documents

Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists

Using isoxazoline XR299 (la) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions α and β to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u1,2 exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of the benzamidin-4-yl moiety with alternative basic groups, elimination of the isoxazoline stereocenter, and reversal of the orientation of the isoxazoline ring resulted in lowered potency and/or duration of action.